Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot study

• Published in: Respiratory medicine Vol. 185; p. 106491
• Main Authors: Crimi, Claudia, Campisi, Raffaele, Nolasco, Santi, Cacopardo, Giulia, Intravaia, Rossella, Porto, Morena, Impellizzeri, Pietro, Pelaia, Corrado, Crimi, Nunzio
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.08.2021
• Subjects: Administration, Oral; Adrenal Cortex Hormones - administration & dosage; Adult; Antibodies, Monoclonal, Humanized - therapeutic use; Asthma - complications; Asthma - drug therapy; Bronchiectasis; Bronchiectasis - complications; Bronchiectasis - drug therapy; Bronchiectasis severity index; Disease Progression; Drug Tapering; Eosinophilia - complications; Eosinophilia - drug therapy; Eosinophils; Female; Humans; Male; Middle Aged; Neutrophils; Patient Acuity; Pilot Projects; Retrospective Studies; Severe eosinophilic asthma; Time Factors; Treatment Outcome; Long-acting muscarinic antagonist; European respiratory society; Neutrophils; Bronchiectasis severity index; Forced expiratory volume in the 1st second; American Thoracic society; Bronchiectasis; Oral corticosteroids; Fractional exhaled nitric oxide; Body mass index; Asthma control test; Chronic rhinosinusitis with nasal polyps; Gastroesophageal reflux disease; Immunoglobulin-E; Severe eosinophilic asthma; Chronic mucus hypersecretion; Eosinophils; Inhaled corticosteroids - Long-acting beta-agonist; Global initiative for asthma

The association of bronchiectasis (BE) in patients with severe eosinophilic asthma (SEA) is quite frequent. Mepolizumab is a well-recognized treatment for SEA; we aim to evaluate its effectiveness in SEA patients with and without BE in real-life. We performed a single-center retrospective pilot stud...